Anetumab ravtansine

製品コードD4011 別名: BAY 94-9343 純度：99%

Anetumab ravtansine (BAY 94-9343) is an antibody-drug conjugate (ADC) composed of a human anti-mesothelin antibody and a cytotoxic maytansinoid tubulin inhibitor DM4. Anetumab ravtansine has the potential to treat advanced solid tumors.

CAS No. 1375258-01-7

サイズ	価格(税別)	在庫状況
1mg	JPY 145500	国内在庫あり
1mg*5	JPY 445500	お問い合わせ

代表番号: 045-509-1970\|電子メール：sales@selleck.co.jp よく尋ねられる質問

文献中Selleckの製品使用例（1）

質量管理及び製品安全説明書

現在のバッチを見る：純度： 99% タンパク質濃度： 6.72mg/ml 内毒素：＜1EU/mg

Antibody-Drug Conjugate阻害剤の選択性比較

生物活性

製品説明	Anetumab ravtansine (BAY 94-9343) is an antibody-drug conjugate (ADC) composed of a human anti-mesothelin antibody and a cytotoxic maytansinoid tubulin inhibitor DM4. Anetumab ravtansine has the potential to treat advanced solid tumors.

参考
https://aacrjournals.org/mct/article/13/6/1537/91847/Anetumab-Ravtansine-A-Novel-Mesothelin-Targeting

参考

https://aacrjournals.org/mct/article/13/6/1537/91847/Anetumab-Ravtansine-A-Novel-Mesothelin-Targeting

製品説明

CAS No.	1375258-01-7
Formulation	100 mM Pro-Ac, 20 mM Arg-Ac, pH5.0
ADC antiody	Anetumab
ADC cytotoxin	DM4
Storage (From the date of receipt)	Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.
Shipping	Shipped under low temperature conditions

各種クローンの論文数比較

^*Selleckは、市場の主要なクローンを収集し、2024年9月までの文献での使用状況を調査しました。その結果、Selleckの選定クローンが最も広く使用されていることが示されました。

臨床試験

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT03816358	ACTIVE_NOT_RECRUITING	Drug: Gemcitabine Hydrochloride	Pancreatic Adenocarcinoma; Stage II Pancreatic Cancer AJCC v8; Stage III Pancreatic Cancer AJCC v8; Stage IV Pancreatic Cancer AJCC v8	National Cancer Institute (NCI)	2019-12-09	PHASE1
NCT03587311	ACTIVE_NOT_RECRUITING	Drug: Paclitaxel	Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube High Grade Serous Adenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian High Grade Serous Adenocarcinoma; Platinum-Resistant Fallopian Tube Carcinoma; Platinum-Resistant Ovarian Carcinoma; Platinum-Resistant Primary Peritoneal Carcinoma; Primary Peritoneal High Grade Serous Adenocarcinoma	National Cancer Institute (NCI)	2018-10-12	PHASE2
NCT03126630	ACTIVE_NOT_RECRUITING		Pleural Malignant Mesothelioma	National Cancer Institute (NCI)	2018-10-04	PHASE1; PHASE2
NCT03926143	TERMINATED	Drug: BAY94-9343 (Anetumab ravtansine)	Solid Tumors	Bayer	2019-06-03	PHASE2
NCT03102320	COMPLETED	Drug: Cisplatin\|Drug: Gemcitabine\|Drug: Anetumab ravtansine	Neoplasms	Bayer	2017-05-26	PHASE1
NCT03455556	TERMINATED		Mesothelin Positive; Stage III Non-Small Cell Lung Cancer AJCC v7; Stage IIIA Non-Small Cell Lung Cancer AJCC v7; Stage IIIB Non-Small Cell Lung Cancer AJCC v7; Stage IV Non-Small Cell Lung Cancer AJCC v7	Mayo Clinic	2018-08-10	PHASE1

(data from https://clinicaltrials.gov, updated on 2026-07-21)

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

* 必須